NCT02846324View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

November 30, 2017

Conditions
Idiopathic Pulmonary FibrosisHypoxemia
Interventions
DRUG

GBT440

Capsules which contain GBT440 drug substance in Swedish orange

DRUG

Placebo

Placebo capsules

Trial Locations (12)

10032

New York

19145

Philadelphia

22042

Falls Church

29425

Charleston

33136

Miami

35233

Birmingham

37212

Nashville

66160

Kansas City

70122

New Orleans

80206

Denver

84108

Salt Lake City

94143

San Francisco

Sponsors
All Listed Sponsors
lead

Global Blood Therapeutics

INDUSTRY

NCT02846324 - Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF | Biotech Hunter | Biotech Hunter